Panlong Pharmaceutical: PLJT-001 Loxoprofen Sodium Gel Patch has received the acceptance notice for domestic drug production registration and marketing license
I'm PortAI, I can summarize articles.
Panlong Pharmaceutical recently announced that its research and development product, Loxoprofen Sodium Gel Patch (PLJT-001), has received the acceptance notice for the marketing authorization application from the National Medical Products Administration. This product is used to treat osteoarthritis, muscle pain, and swelling or pain after injury, with significant anti-inflammatory and analgesic effects, as well as low irritation and good skin compatibility, enhancing the comfort and convenience of medication
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments